go to contents

Zytoprotec GmbH

Back to list

Facts

Founded
2007
Staff
7
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

Our mission is to make a novel therapeutic approach a reality in Peritoneal Dialysis (PD) – an area where clinicians and patients saw disappointingly little innovation in decades. Zytoprotec, a biomedical company founded in 2007, has consistently moved its lead product – PDprotec® – from basic research through preclinical and clinical development. The product is currently prepared to enter a pivotal Phase III clinical trial.

R&D:Research conducted by Zytoprotec has shown that the protective mechanism of cells can be restored by intervention with cytoprotective compounds. This offers the potential to prevent cells, tissues and whole organs from damage, thereby improving the quality of live and the survival of patients. With PDprotec®, Zytoprotec is applying this new approach to the area of renal replacement therapy.

Similar companies in RDM biotech/pharma

igor - Institut für Gewebe und Organrekonstruktion Ges.m.b.H.

Organization type
RDM biotech/pharma
Region
Upper Austria
Cluster
Medical Technology Cluster
Focus
human health
Details

Intervet GesmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
animal health
Details

AMGEN GMBH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Vivaldi Biosciences AG

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Contact

Mariannengasse 28/2
1090 Wien
Vienna

Contact: Bernd Seibel (Geschäftsführer)
Email: office@zytoprotec.com
Website